Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases primarily in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. This segment also offers SGX942, a novel innate defense regulator technology that is in Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has been completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. These vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.
http://www.priceseries.com/trade/SNGX-Soligenix-Inc-stock-gains-54-percent-a-Trade-Record-by-priceSeries-2019120320200114.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments